

Index to Volume 28

Index au volume 28

The *Journal of Psychiatry & Neuroscience* is indexed according to the medical subject headings established by the National Library of Medicine, US National Institutes of Health.

The title for each article is followed by a code that designates the article's category. The categories used in this volume are listed below.

La *Revue de psychiatrie & de neuroscience* est indexée par vedette-matière selon la nomenclature de la National Library of Medicine des National Institutes of Health américains.

Chaque titre d'article est suivi d'un code indiquant à quelle catégorie l'article appartient. Les catégories utilisées dans ce volume sont les suivantes :

Book Review / Recension (Book)
Brief Report / Rapport sommaire (Brief)
CCNP News and Views / Nouvelles et opinions du CCNP (CCNP)
Commentary / Commentaire (Comm)
Debate / Débat (Debate)
Editorial / Éditorial (E)
Letter to the Editors / Correspondance (L)
Psychopharmacology for the Clinician / Psychopharmacologie pratique (Psychopharm)
Research Paper / Article de recherche (Res)
Review Paper / Examen critique (Rev)

Subjects / Sujets

- A -

Acetylcholine

- Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13
- Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Adverse drug reaction reporting systems

- A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

Aggression

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468
- What is a recommended treatment for aggression in a patient with schizophrenia? (Gobbi and Debonnel) (Psychopharm) 320

Aging

- Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Agmatine

- Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Alcohol drinking

- The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263
- Substance use and cognition in early psychosis (Pencer and Addington) (Res) 48

Alcoholism

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468
- The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263
- What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80

Alleles

- Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Alzheimer disease

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468
- Buspiron for anxiety and agitation in dementia (Cooper) (L) 469
- Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Amine oxidase (copper-containing)

- Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Amygdala

- Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

Amyloid beta-protein precursor

- Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Anorexia nervosa

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

Antidepressive agents

- Antidepressants and suicide: risk-benefit conundrums (Healy and Whitaker) (Debate) 331
- Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210
- Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409
- Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers (Won and others) (L) 134
- Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55
- Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340
- Treating mood disorders (Joffe) (E) 9

Antipsychotic agents

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468
- Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293
- Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39
- Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99
- Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247
- A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253
- Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240
- Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275

Anxiety

- Buspiron for anxiety and agitation in dementia (Cooper) (L) 469
- Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

Apolipoproteins E

- Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Attention deficit disorder with hyperactivity

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

- Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27
- Auditory pathways**
Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432
- Autistic disorder**
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
- B -
- Beclomethasone**
Beclomethasone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364
- Behavior, addictive**
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
- Behavioral research**
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171
- Behavioral symptoms**
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lanctôt and others) (Rev) 13
- Binding sites**
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409
- Biogenic amines**
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409
- Biotransformation**
Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99
- Bipolar disorder**
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca^{2+} levels (Ulrich and others) (Res) 115
Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240
Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134
Treating mood disorders (Joffe) (E) 9
- Blood platelets**
Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca^{2+} levels (Ulrich and others) (Res) 115
- Book review**
Foundations in Social Neuroscience (Young and Moskowitz) (Book) 375
Handbook and Transcranial Magnetic Stimulation (Nahas) (Book) 373
Mood Disorders in Women (Calhoun) (Book) 139
Psychiatric Medications for Older Adults: The Concise Guide (Sadavoy) (Book) 140
Psychiatry in Canada: Fifty Years (Joffe) (Book) 377
Psychiatry in the Elderly (Lok and Le Clair) (Book) 376
The Psychopharmacology of Herbal Medicine: Plant Drugs That Alter Mind, Brain and Behavior (Coutts) (Book) 300
- Botulinum toxin type A**
Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240
- Brain**
Anterior cingulate dysfunction: Implications for psychiatric disorders? (Yücel and others) (Comm) 350
- Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432
- Brain mapping**
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
- Brief psychiatric rating scale**
Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39
- Bromocriptine**
What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80
- Bulimia**
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
- Buspirone**
Buspirone for anxiety and agitation in dementia (Cooper) (L) 469
What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80
- C -
- Calcium**
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca^{2+} levels (Ulrich and others) (Res) 115
- Cannabis**
Substance use and cognition in early psychosis (Pencer and Addington) (Res) 48
- Carbamazepine**
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca^{2+} levels (Ulrich and others) (Res) 115
- Case-control studies**
Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27
- Catecholamines**
A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464
- Central nervous system**
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
- Cerebral cortex**
Anterior cingulate dysfunction: Implications for psychiatric disorders? (Yücel and others) (Comm) 350
- China**
Smoking and tardive dyskinesia: lack of involvement of the *CYP1A2* gene (Chong and others) (Res) 185
- Cholecystokinin**
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171
- Cholesterol**
Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol (Morrow and others) (Res) 127
- Cholinesterase inhibitors**
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lanctôt and others) (Rev) 13
- Chronic disease**
Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55
- Clonidine**
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Clozapine

- Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275
 What is a recommended treatment for aggression in a patient with schizophrenia? (Gobbi and Debonnel) (Psychopharm) 320

Cognition disorders

- Substance use and cognition in early psychosis (Pencer and Addington) (Res) 48

Cytochrome P-450 CYP1A2

- Smoking and tardive dyskinesia: lack of involvement of the *CYP1A2* gene (Chong and others) (Res) 185

Cytochrome P-450 enzyme system

- Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99

- D -**Dementia**

- Buspiron for anxiety and agitation in dementia (Cooper) (L) 469
 Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Depression

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
 Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers (Won and others) (L) 134

Depressive disorder

- Beclomethasone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364
 Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355
 Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210
 Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55
 Repetitive transcranial magnetic stimulation for depression (Cooke) (Psychopharm) 400
 Treating mood disorders (Joffe) (E) 9

Dextroamphetamine

- Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca^{2+} levels (Ulrich and others) (Res) 115

Diagnosis

- The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Diazepam

- Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452

Disease

- Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87

Disease progression

- The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Dopamine

- Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171
 Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27
 Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247
 A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464
 Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275

Dreams

- Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Drug interactions

- Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99

Drug resistance

- Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55

Drug therapy

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
 Brand versus generic medications: the money, the patient and the research (Blier) (E) 167
 Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca^{2+} levels (Ulrich and others) (Res) 115
 Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87
 Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247

Drug therapy, combination

- Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355
 Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Drug toxicity

- Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55
 A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

Dyskinesias

- Smoking and tardive dyskinesia: lack of involvement of the *CYP1A2* gene (Chong and others) (Res) 185

Dystonia

- Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240

- E -**Eating disorders**

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Editorial policies

- Peer review of manuscripts: theory and practice (Young) (E) 327

Electroconvulsive therapy

- Repetitive transcranial magnetic stimulation for depression (Cooke) (Psychopharm) 400

Electroencephalography

- Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Emotions

- Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452
 Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87

Epidemiology

- Antidepressants and suicide: risk-benefit conundrums (Healy and Whitaker) (Debate) 331
 Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340

Epilepsy

- Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Estradiol

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Ethanol

The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Ethinyl estradiol

Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreat-ment with ethinyl estradiol (Morrow and others) (Res) 127

- F -**Facial expression**

Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452

Fatty acids, nonesterified

Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreat-ment with ethinyl estradiol (Morrow and others) (Res) 127

Fetal alcohol syndrome

The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Fura-2

Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca²⁺ levels (Ulrich and others) (Res) 115

- G -**Gamma-aminobutyric acid**

Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452

The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Gene expression

The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

Genetic predisposition to disease

Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Molecular genetics of schizophrenia: a critical review (Berry and others) (Rev) 415

The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Smoking and tardive dyskinesia: lack of involvement of the *CYP1A2* gene (Chong and others) (Res) 185

Genetics, behavioral

Molecular genetics of schizophrenia: a critical review (Berry and others) (Rev) 415

Glucocorticoid

Beclomethasone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364

Glutamic acid

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275

Gyrus cinguli

Anterior cingulate dysfunction: Implications for psychiatric disorders? (Yücel and others) (Comm) 350

- H -**Hallucinations**

Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Left with the voices or hearing right? Lateralization of auditory verbal hallucinations in schizophrenia (Sommer and others) (L) 217; Reply (Stip and Ait Bentaleb) (L) 218

Haloperidol

Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293

Health services

The University of Ottawa model for obtaining the needed spectrum of psychiatric services: its relevance in the world today (Sarwer-Foner) (CCNP) 136

Hydrocortisone

Beclomethasone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364

5-Hydroxytryptophan

Are SAME and 5-HTP safe and effective treatments for depression? (Young) (Psychopharm) 471

Hypertension

Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Hypothyroidism

Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

- I -**Imidazoles**

Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Ion channel gating

The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

- L -**Legislation, drug**

Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87

Linkage (genetics)

Molecular genetics of schizophrenia: a critical review (Berry and others) (Rev) 415

Lithium carbonate

Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355

Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

Lithium chloride

Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca²⁺ levels (Ulrich and others) (Res) 115

Loxapine

Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39

- M -**Magnetic resonance imaging**

Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247

Melatonin

Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study (Almeida Montes and others) (Res) 191

Memory disorders

Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Mental disorders

Anterior cingulate dysfunction: Implications for psychiatric disorders? (Yücel and others) (Comm) 350

Mental health services

The University of Ottawa model for obtaining the needed spectrum of psychiatric services: its relevance in the world today (Sarwer-Foner) (CCNP) 136

Meta-analysis

- Antidepressants and suicide: risk-benefit conundrums (Healy and Whitaker) (Debate) 331
- Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27
- Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340

Metabolism

- Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99

Methamphetamine

- Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers (Won and others) (L) 134

Minisatellite repeats

- Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Models, animal

- Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171
- Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Molecular biology

- Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Monitoring, ambulatory

- Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293

Monoamine oxidase

- Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Mood disorders

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468
- Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87
- Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247
- Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

Motivation

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

Motor activity

- Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293

Movement disorders

- Smoking and tardive dyskinesia: lack of involvement of the *CYP1A2* gene (Chong and others) (Res) 185

- N -

Naltrexone

- What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80

Neuropharmacology

- Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Nitric oxide

- Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia (Suzuki and others) (Res) 288

Norepinephrine

- A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Nucleus accumbens

- Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

- O -

Olanzapine

- Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293
- A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

Overdose

- A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

- P -

Panic disorder

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468
- Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol (Morrow and others) (Res) 127

Parkinson disease

- The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

Patents

- Brand versus generic medications: the money, the patient and the research (Blier) (E) 167

Patient care

- The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Peer review, research

- Peer review of manuscripts: theory and practice (Young) (E) 327

Pentagastrin

- Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol (Morrow and others) (Res) 127

Perception

- Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452

Periodicals

- Peer review of manuscripts: theory and practice (Young) (E) 327

Phenylalanine

- A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Phosphatidylinositols

- Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca^{2+} levels (Ulrich and others) (Res) 115

Polymorphism, genetics

- Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Prescriptions, drug

- Brand versus generic medications: the money, the patient and the research (Blier) (E) 167

Psychiatric status rating scales

- Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39
- The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Psychiatry

- The University of Ottawa model for obtaining the needed spectrum

of psychiatric services: its relevance in the world today (Sarwer-Foner) (CCNP) 136

Psychopharmacology

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275

Psychotherapy

What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80

Psychotic disorders

Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Substance use and cognition in early psychosis (Pencer and Addington) (Res) 48

Publishing

Peer review of manuscripts: theory and practice (Young) (E) 327

- R -

Rats, inbred SHR

Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Receptors, cholecystokinin

Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

Receptors, cholinergic

Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Receptors, dopamine

The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275

Receptors, GABA_A

The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Receptors, serotonin

Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39

Receptors, vasoconstriction

Beclomethasone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364

Remission induction

Treating mood disorders (Joffe) (E) 9

Research

Peer review of manuscripts: theory and practice (Young) (E) 327

Rett syndrome

The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

Reward

The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

Risk factors

The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

- S -

S-Adenosylmethionine

Are SAME and 5-HTP safe and effective treatments for depression? (Young) (Psychopharm) 471

Schizophrenia

The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (Leyton and others) (CCNP) 468

Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39

Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99

Left with the voices or hearing right? Lateralization of auditory verbal hallucinations in schizophrenia (Sommer and others) (L) 217; Reply (Stip and Ait Bentaleb) (L) 218

Molecular genetics of schizophrenia: a critical review (Berry and others) (Rev) 415

Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247

Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia (Suzuki and others) (Res) 288

Smoking and tardive dyskinesia: lack of involvement of the *CYP1A2* gene (Chong and others) (Res) 185

Substance use and cognition in early psychosis (Pencer and Addington) (Res) 48

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275

What is a recommended treatment for aggression in a patient with schizophrenia? (Gobbi and Debonnel) (Psychopharm) 320

Schizophrenia and disorders with psychotic features

The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Self medication

Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87

Serotonin

Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247

A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275

Serotonin syndrome

Is tryptophan a natural hypnotic? (Young) (Psychopharm) 160

Serotonin uptake inhibitors

Antidepressants and suicide: risk-benefit conundrums (Healy and Whitaker) (Debate) 331

Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers (Won and others) (L) 134

Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340

Sex factors

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Signs and symptoms

Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia (Suzuki and others) (Res) 288

The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Sleep initiation and maintenance disorders

Is tryptophan a natural hypnotic? (Young) (Psychopharm) 160

Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study (Almeida Montes and others) (Res) 191

Smoking

Smoking and tardive dyskinesia: lack of involvement of the *CYP1A2* gene (Chong and others) (Res) 185

Steroids

The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Substance-related disorders

Substance use and cognition in early psychosis (Pencer and Addington) (Res) 48

Suicide

The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Antidepressants and suicide: risk–benefit conundrums (Healy and Whitaker) (Debate) 331

A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340

- T -**Tacrine**

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Technology, pharmaceutical

Brand versus generic medications: the money, the patient and the research (Blier) (E) 167

Thyroid hormones

Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

Thyrotropin

Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Thyroxine

Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Tomography, emission-computed, single-photon

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Torticollis

Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240

Treatment outcome

Antidepressants and suicide: risk–benefit conundrums (Healy and Whitaker) (Debate) 331

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Lancôt and others) (Rev) 13

Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355

Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55

The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340

Treating mood disorders (Joffe) (E) 9

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Remington) (Rev) 275

Triiodothyronine

Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Tryptamines

Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Tryptophan

Brand versus generic medications: the money, the patient and the research (Blier) (E) 167

Is tryptophan a natural hypnotic? (Young) (Psychopharm) 160

A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Tyrosine

A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

- V -**Valproic acid**

Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca²⁺ levels (Ulrich and others) (Res) 115

Visual pathways

Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

- W -**Women**

Beclomethasone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364

Writing

Peer review of manuscripts: theory and practice (Young) (E) 327

Authors / Auteurs**- A -****Addington J**

The prodromal stage of psychotic illness: Observation, detection or intervention? (Comm) 93

Addington J See **Pencer A** Jt Auth

Adli M See **Bschor T** Jt Auth

Ait Bentaleb L See **Stip E** Jt Auth

Aleman A See **Sommer IEC** Jt Auth

Almeida Montes LG, Ontiveros Uribe MP, Cortés Sotres J, Heinze Martin G

Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study (Res) 191

Asgar SJ See **Ulrich ML** Jt Auth

- B -

Baethge C, Gruschka P, Smolka MN, Berghöfer A, Bschor T, Müller-Oerlinghausen B, Bauer M

Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Res) 355

Baethge C See **Bschor T** Jt Auth

Baker GB See **Prior TI** Jt Auth

Barlas C See **Singh AN** Jt Auth

Bauer M See **Baethge C** Jt Auth; **Bschor T** Jt Auth

Bellavance F See **Morrow JD** Jt Auth

Benkelfat C See **Leyton M** Jt Auth

Berghöfer A See **Baethge C** Jt Auth

Berry N, Jobanputra V, Pal H

Molecular genetics of schizophrenia: a critical review (Rev) 415

Blair RJ See **Coupland NJ** Jt Auth

Blier P

Brand versus generic medications: the money, the patient and the research (E) 167

Braun CMJ, Dumont M, Duval J, Hamel-Hébert I, Godbout L

Brain modules of hallucination: an analysis of multiple cases of lesions (Rev) 432

Bschor T, Baethge C, Adli M, Lewitzka U, Eichmann U, Bauer M
Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Brief) 210

Bschor T See **Baethge C** Jt Auth

- C -

Calhoun L

Mood Disorders in Women (Book) 139

Chong SA, Tan EC, Tan CH, Mythily

Smoking and tardive dyskinesia: lack of involvement of the *CYP1A2* gene (Res) 185

Chrapko W See **Morrow JD** Jt Auth

Christensen BK See **Kiang M** Jt Auth

Chue P, Singer P

A review of olanzapine-associated toxicity and fatality in overdose (Rev) 253

Cooke RG

Repetitive transcranial magnetic stimulation for depression (Psychopharm) 400

Cooper JP

Buspirone for anxiety and agitation in dementia (L) 469

Cortés Sotres J See **Almeida Montes LG** Jt Auth

Coupland NJ, Hegadoren KM, Myrholm J

Beclomethasone-induced vasoconstriction in women with major depressive disorder (Res) 364

Coupland NJ, Singh AJ, Sustrik RA, Ting P, Blair RJ

Effects of diazepam on facial emotion recognition (Res) 452

Coutts RT

The Psychopharmacology of Herbal Medicine: Plant Drugs That Alter Mind, Brain and Behavior (Book) 300

- D -

Daskalakis J See **Kiang M** Jt Auth

Davies M

The role of GABA_A receptors in mediating the effects of alcohol in the central nervous system (Rev) 263

Debonnel G See **Gobbi G** Jt Auth

DiMaio S, Grizenko N, Joober R

Dopamine genes and attention-deficit hyperactivity disorder: a review (Rev) 27

Dongier M

What treatment options exist for alcohol abuse? (Psychopharm) 80

Dumont M See **Braun CMJ** Jt Auth

Dunn SMJ See **Ulrich ML** Jt Auth

Duval J See **Braun CMJ** Jt Auth

- E -

Eichmann U See **Bschor T** Jt Auth

- F -

Fornito A See **Yücel M** Jt Auth

- G -

Gobbi G, Debonnel G

What is a recommended treatment for aggression in a patient with schizophrenia? (Psychopharm) 320

Godbout L See **Braun CMJ** Jt Auth

Greenshaw AJ

Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (E) 247

Greenshaw A See **Ulrich ML** Jt Auth

Grizenko N See **DiMaio S** Jt Auth

Gruschka P See **Baethge C** Jt Auth

- H -

Hamel-Hébert I See **Braun CMJ** Jt Auth

Healy D, Whitaker C

Antidepressants and suicide: risk-benefit conundrums (Debate) 331

Hegadoren KM See **Coupland NJ** Jt Auth

Heinze Martin G See **Almeida Montes LG** Jt Auth

Hernandez CM, Høifødt H, Terry AV Jr

Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Res) 197

Herrmann N See **Lancôt KL** Jt Auth

Høifødt J See **Hernandez CM** Jt Auth

Holt A

Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (E) 409

- J -

Jobanputra V See **Berry N** Jt Auth

Joffe RT

Psychiatry in Canada: Fifty Years (Book) 377
Treating mood disorders (E) 9

Joober R See **DiMaio S** Jt Auth; **Leyton M** Jt Auth

Jurasz P See **Ulrich ML** Jt Auth

- K -

Kahn RS See **Sommer IEC** Jt Auth

Kapur S See **Kiang M** Jt Auth

Kiang M, Daskalakis ZJ, Christensen BK, Remington G, Kapur S

Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Res) 293

Kondo N See **Won M** Jt Auth

Kundhur D See **Wan DDC** Jt Auth

Kwai Pun V See **Leyton M** Jt Auth

- L -

Lam RW See **Wan DDC** Jt Auth

Lancôt KL, Herrmann N, LouLou MM

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease (Rev) 13

Lapierre YD

Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Debate) 340

Lara N See **Morrow JD** Jt Auth

Le Clair JK See **Lok JS** Jt Auth

Le Mellédo JM See **Morrow JD** Jt Auth

Lewitzka U See **Bschor T** Jt Auth

Leyton M, Joober R, Young SN

The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1-4, 2003 (CCNP) 468

Leyton M, Kwai Pun V, Benkelfat C, Young SN

A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Brief) 464

Lok JS, Le Clair JK

Psychiatry in the Elderly (Book) 376

LouLou MM See **Lancôt KL** Jt Auth

- M -

McManus K See **Morrow JD** Jt Auth

Mazurek MF See **Rosebush PI** Jt Auth

- Minabe Y** See **Won M** Jt Auth
Mishra RK See **Singh AN** Jt Auth
Miyaoka H See **Suzuki E** Jt Auth
Mori N See **Won M** Jt Auth
Morrow JD, McManus K, Tait GR, Bellavance F, Chrapko W, Lara N, Le Mellédo JM
 Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol (Res) 127
Moskowitz DS See **Young SN** Jt Auth
Müller-Oerlinghausen B See **Baethge C** Jt Auth
Myrholm J See **Coupland NJ** Jt Auth
Mythily See **Chong SA** Jt Auth
- N -
- Nahas Z**
Handbook of Transcranial Magnetic Stimulation (Book) 373
Nakaki T See **Suzuki E** Jt Auth
Nakamura M See **Suzuki E** Jt Auth
- O -
- Ontiveros Uribe MP** See **Almeida Montes LG** Jt Auth
- P -
- Pal H** See **Berry N** Jt Auth
Pantelis C See **Yücel M** Jt Auth
Pencer A, Addington J
 Substance use and cognition in early psychosis (Res) 48
Prior TI, Baker GB
 Interactions between the cytochrome P450 system and the second-generation antipsychotics (Rev) 99
- R -
- Radomski M** See **Ulrich ML** Jt Auth
Ramasubbu R
 Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (L) 134
Remington G
 Understanding antipsychotic "atypicality": a clinical and pharmacological moving target (Rev) 275
Remington G See **Kiang M** Jt Auth
Riffkin J See **Yücel M** Jt Auth
Rosebush PI, Mazurek MF
 Tardive dystonia and its treatment (Psychopharm) 240
Rotzinger S See **Ulrich ML** Jt Auth
Rotzinger S, Vaccarino FJ
 Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rev) 171
- S -
- Sadavoy J**
Psychiatric Medications for Older Adults: The Concise Guide (Book) 140
Saeedi H See **Singh AN** Jt Auth
Sarwer-Foner GJ
 The University of Ottawa model for obtaining the needed spectrum of psychiatric services: its relevance in the world today (CCNP) 136
Sekine Y See **Won M** Jt Auth
Silverstone PH See **Ulrich ML** Jt Auth
Singer P See **Chue P** Jt Auth
- Singh AJ** See **Coupland NJ** Jt Auth
Singh AN, Barlas C, Saeedi H, Mishra RK
 Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Res) 39
Smolka MN See **Baethge C** Jt Auth
Solomons K See **Wan DDC** Jt Auth
Sommer IEC, Aleman A, Kahn RS
 Left with the voices or hearing right? Lateralization of auditory verbal hallucinations in schizophrenia (L) 217
Stip E, Ait Bentaleb L
 Left with the voices or hearing right? Lateralization of auditory verbal hallucinations in schizophrenia. Reply (L) 218
Sustrik RA See **Coupland NJ** Jt Auth
Suzuki E, Nakaki T, Nakamura M, Miyaoka H
 Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia (Res) 288
- T -
- Tait GR** See **Morrow JD** Jt Auth
Takei N See **Won M** Jt Auth
Tan CH See **Chong SA** Jt Auth
Tan EC See **Chong SA** Jt Auth
Tanay VA See **Ulrich ML** Jt Auth
Terry AV Jr See **Hernandez CM** Jt Auth
Ting P See **Coupland NJ** Jt Auth
- U -
- Ulrich ML, Rotzinger S, Asghar SJ, Jurasz P, Tanay VA, Dunn SMJ, Radomski M, Greenshaw A, Silverstone PH**
 Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca²⁺ levels (Res) 115
- V -
- Vaccarino FJ** See **Rotzinger S** Jt Auth
Velakoulis D See **Yücel M** Jt Auth
- W -
- Wan DDC, Kundhur D, Solomons K, Yatham LN, Lam RW**
 Mirtazapine for treatment-resistant depression: a preliminary report (Brief) 55
Whitaker C See **Healy D** Jt Auth
Won M, Minabe Y, Sekine Y, Takei N, Kondo N, Mori N
 Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers (L) 134
Wood SJ See **Yücel M** Jt Auth
- Y -
- Yatham LN** See **Wan DDC** Jt Auth
Young SN
 Are SAME and 5-HTP safe and effective treatments for depression? (Psychopharm) 471
 Is tryptophan a natural hypnotic? (Psychopharm) 160
 Lifestyle drugs, mood, behaviour and cognition (E) 87
 Peer review of manuscripts: theory and practice (E) 327
Young SN, Moskowitz DS
Foundations in Social Neuroscience (Book) 375
Young SN See **Leyton M** Jt Auth
Yücel M, Wood SJ, Fornito A, Riffkin J, Velakoulis D, Pantelis C
 Anterior cingulate dysfunction: Implications for psychiatric disorders? (Comm) 350